Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.46 |
| ▸ | RELA | Q04206 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684464 | 0.81 | KDM4E (0.52) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL16601901 | 0.80 | KDM4E (0.59) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL23367954 | 0.79 | APP (0.44) | ALDH1A1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL27667559 | 0.79 | NOTUM (0.53) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL17101469 | 0.79 | KDM4E (0.57) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1523919 | 0.79 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2MAPTKDM4ELMNA | |
| SCHEMBL185735 | 0.76 | HSD17B1 (0.61) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2096089 | 0.76 | NPC1 (0.50) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL16652089 | 0.75 | LOXL2 (0.37) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL20379368 | 0.75 | HSD17B1 (0.53) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297168-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-11-20 | — | — | US | claimed |
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-09-15 | — | — | US | claimed |
| WO-2024151666-A1 | CARBOXYLIC ACID ANALOGS AS GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| EP-2976327-A2 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| CN-105228982-A | 3-acetylamino-1- (phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino) benzene derivatives for the treatment of hyperproliferative disorders | Bayer Pharma AG | 2016-01-06 | — | — | CN | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140179735-A1 | TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF TO MODULATE THE ACTIVITY OF ENZYMESp INVOLVED IN THE PATHOLOGY OF MYCOBACTERIUM TUBERCULOSIS | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2014-06-26 | — | — | US | disclosed |
| US-7297168-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| CN-1913865-A | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE (US) | 2007-02-14 | — | — | CN | disclosed |
| EP-1737417-A2 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter and Gamble Company (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-09-15 | — | — | US | disclosed |
| WO-2005074875-A2 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | ALDH1A1 300/4885NPC1 2436/4885RAB9A 519/4885 |
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | ALDH1A1 743/4885NPC1 3116/4885RAB9A 3037/4885 |
| US-20140179735-A1 | TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF TO MODULATE THE ACTIVITY OF ENZYMESp INVOLVED IN THE PATHOLOGY OF MYCOBACTERIUM TUBERCULOSIS | PPP3CB, PPP4C, PTPRB | ALDH1A1 803/4885NPC1 4752/4885RAB9A 2616/4885 |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | ALDH1A1 743/4885NPC1 3116/4885RAB9A 3037/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | ALDH1A1 300/4885NPC1 2436/4885RAB9A 519/4885 |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, IRF3, CGAS | ALDH1A1 4473/4885NPC1 517/4885RAB9A 928/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | ALDH1A1 285/4885NPC1 2546/4885RAB9A 480/4885 |
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, CYB5R3 | ALDH1A1 782/4885NPC1 4814/4885RAB9A 4235/4885 |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4654/4885NPC1 859/4885RAB9A 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.